Cardiology Update

APRIL 25, 2024

The primary endpoint was a composite of all-cause mortality, left ventricular assist device (LVAD)/heart transplantation, HF hospitalizations, worsening HF, and KCCQ score changes. Among patients with HFpEF, those who received the shunt experienced poor outcomes than those who did not. Learn more about the highlights from ACC 2024.

Heart Failure 98

Heart Failure Heart Transplant Transplant Research 98

Cardiovascular Diabetology

FEBRUARY 20, 2025

Cardiovascular disease is a leading cause of post-transplant mortality in kidney transplant recipients (KTRs), especially those with diabetes. Although glucagon-like peptide-1 receptor agonists (GLP-1 RAs) hav.

Transplant 52

Transplant Diabetes Cardiovascular Disease Outcomes 52

Journal of Cardiothoracic Surgery

FEBRUARY 9, 2024

We examine the factors associated with heart transplant outcomes in this challenging population with complex anatomy requiring redo-sur. Adult patients surviving with congenital heart disease (ACHD) is growing.

Congenital Heart Disease 52

Congenital Heart Disease Heart Transplant Transplant Congenital 52

Circulation

MARCH 11, 2024

Hematopoietic stem cell transplantation can cure various disorders but poses cardiovascular risks, especially for elderly patients and those with cardiovascular diseases. Cardiovascular evaluations are crucial in pretransplantation assessments, but guidelines are lacking.

Transplant 45

Transplant Cardiovascular Disease Atrial Fibrillation Pediatrics 45

DAIC

MARCH 6, 2024

Food and Drug Adminstration (FDA) has approved DEFINITY (Perflutren Lipid Microsphere) as an ultrasound enhancing agent for use in pediatric patients with suboptimal echocardiograms, including those who have undergone heart transplant, or have Kawasaki disease or a congenital cardiovascular anomaly. 3 ©2021 Millennium Research Group, Inc.

Pediatrics 105

Pediatrics Ultrasound Heart Transplant Echocardiogram 105

Frontiers in Cardiovascular Medicine

FEBRUARY 24, 2025

BackgroundLung transplantation (LTx) is the definitive treatment for end-stage pulmonary diseases, with venoarterial extracorporeal membrane oxygenation (VA-ECMO) used as a common perioperative support. Data included recipient/donor demographics, preoperative status, and follow-up outcomes.

Transplant 40

Transplant ICU Pulmonary Hospital 40

European Journal of Heart Failure

NOVEMBER 9, 2023

However, data on long-term outcome after upgrade to CRT are scarce. The primary composite endpoint included all-cause mortality, heart transplantation, or ventricular assist device implantation.

Outcomes 40

Outcomes Heart Failure Heart Transplant Defibrillator 40

Stroke Journal

FEBRUARY 1, 2024

Introduction:Intraparenchymal stem cell transplantation shows therapeutic promise for chronic ischemic stroke patients. Visium identified specific gene clusters for the stroke injury, transplant/needle-track, stem cell graft, and the cortical ‘FLAIR’ region. Stroke, Volume 55, Issue Suppl_1 , Page ATP286-ATP286, February 1, 2024.

Transplant 40

Transplant Stroke Strokes Research 40

European Journal of Heart Failure

DECEMBER 13, 2023

Venn diagram of iron deficiency (ID) according to various definitions and associated outcomes. We evaluated three definitions of ID in patients referred for heart transplantation. Methods and results Consecutive patients assessed for heart transplantation at a single UK centre between January 2010 and May 2022 were included.

Heart Failure 40

Heart Failure Heart Transplant Transplant Pulmonary 40

Society of Thoracic Surgeons - Technology

JANUARY 19, 2022

With her fellowship, Dr. Fiedler plans to learn skills and administrative approaches that will help her expand the heart transplant program at UW-Madison, where she currently serves as associate director of heart transplantation and mechanical circulatory support. For more information, visit sts.org.

Cardiothoracic 52

Cardiothoracic Heart Transplant Allied Health Education 52

Society of Thoracic Surgeons - Research

MAY 5, 2023

About Annals of Thoracic Surgery Short Reports Annals of Thoracic Surgery Short Reports —the official fully open access companion journal to The Annals of Thoracic Surgery —provides a modern venue for authors to present their research in a digestible format, while also making it available immediately, permanently, and universally.

Article 40

Article Cardiothoracic Education Congenital 40

Open Heart

MAY 25, 2022

Methods The primary outcome was the prevalence and incidence of TE in the patients with LVNC. The secondary outcome was the TE and mortality and heart transplantation rates between paediatric and adult patients with LVNC. Studies that did not present original research, non-human studies, duplicated studies were excluded.

Heart Transplant 40

Heart Transplant Transplant Risk Factors Outcomes 40

European Journal of Heart Failure

NOVEMBER 19, 2024

The survey investigated four areas: guideline awareness, healthcare network organization, clinical case management, and perceptions of mechanical circulatory support (MCS) outcomes. Respondents were categorized into heart failure cardiologists (HFCs), general cardiologists (GCs), and other participants (OPs). of HFCs, 19.6% of GCs, and 18.2%

Heart Failure 40

Heart Failure Transplant Heart Transplant Education 40

Stroke Journal

FEBRUARY 1, 2024

CPB is utilized for heart and lung transplants, aorta repairs, valve surgeries, mass resections, and coronary artery bypass grafting (CABG) which alone accounts for 400k patients per year. Outcomes included number and distribution of CMBs, presence of superficial siderosis, FAZEKAS, and CPB duration.

Coronary Artery Bypass Graft 40

Coronary Artery Bypass Graft Transplant Patient Care Research 40

European Journal of Heart Failure

FEBRUARY 25, 2025

Abstract Aims The CASTLE-HTx trial showed the benefit of atrial fibrillation (AF) ablation compared to medical therapy in decreasing mortality, need for left ventricular assist device implantation or heart transplantation (HTx) in patients with end-stage heart failure (HF).

Atrial Fibrillation 40

Atrial Fibrillation Ablation Heart Failure Arrhythmia 40

MIBHS

SEPTEMBER 30, 2024

The fear of the unknown, of potential surgeries, and of long-term outcomes can be paralyzing. This fear can be compounded by the uncertainty surrounding the condition, as each CHD case is unique, and outcomes can vary widely. The Children’s Heart Foundation : Focuses on funding research for CHDs and provides resources for families.

Congenital 52

Congenital Education Open-Heart Surgery Pediatrics 52

DAIC

APRIL 30, 2024

Image courtesy of Hideki Kobayashi from Shinshu University milla1cf Tue, 04/30/2024 - 12:53 April 30, 2024 — Regenerative heart therapies involve transplanting cardiac muscle cells into damaged areas of the heart to recover lost function. The highly positive outcomes observed in primate models highlight the potential of this strategy.

Transplant 105

Transplant Heart Transplant Myocardial Infarction Heart attacks 105

European Journal of Heart Failure

APRIL 13, 2025

The primary outcome was all-cause death and heart transplantation. Secondary heart failure (HF) and arrhythmic outcomes were also included. Conclusion Relatives of DCM/NDLVC probands who developed LV systolic dysfunction during a long follow-up had a significant increased risk of major adverse cardiovascular outcomes.

Cardiomyopathy 40

Cardiomyopathy Heart Transplant Electrocardiogram Transplant 40

DAIC

APRIL 6, 2024

While the trial did not meet its primary endpoint, it moves the field forward by offering signals that the benefits and risks of interatrial shunts may vary by heart failure type, according to researchers. Researchers tracked outcomes in each participant for at least one year and up to two years.

Heart Failure 81

Heart Failure Quality of Life Outcomes Preserved Ejection Fraction 81

DAIC

DECEMBER 8, 2023

a medical device company dedicated to improving outcomes for patients with cardiac and renal impairment, announced the enrollment of the first patients in the company's IDE pivotal trial. These patients have very poor outcomes in terms of death and rehospitalization and therefore new therapy options are critically needed," stated Dr. Chehab.

Technology 113

Technology Heart Failure Heart Transplant Transplant 113

Cardiology Update

JANUARY 22, 2024

Long-term outcomes were assessed at the eight highest-enrolling sites. The primary outcome was death from any cause, and the secondary outcome included a composite of death, heart transplantation, or ventricular assist device implantation. Secondary outcomes were experienced by 77.7% to 0.92; P=0.002).

Heart Failure 115

Heart Failure Defibrillator Heart Transplant Transplant 115

DAIC

APRIL 6, 2024

While the trial did not meet its primary endpoint, it moves the field forward by offering signals that the benefits and risks of interatrial shunts may vary by heart failure type, according to researchers. Researchers tracked outcomes in each participant for at least one year and up to two years.

Heart Failure 75

Heart Failure Quality of Life Preserved Ejection Fraction Hospital 75

DAIC

MARCH 13, 2024

To my knowledge, no therapy has been proven to reduce mortality in these patients, and CardiAMP Heart Failure II has great potential to achieve this outcome by confirming our CardiAMP Heart Failure Trial results.” The study includes an eligibility requirement that patients demonstrate a pre-specified NT-proBNP level at baseline.

CMS 111

CMS Heart Failure Reimbursement Quality of Life 111

Cardiometabolic Health Congress

AUGUST 8, 2024

This blog post explores the development of such partnerships and their potential to transform healthcare outcomes. Engaging individuals as active participants in their care plans can significantly enhance outcomes and improve overall quality of life.

Education 59

Education Cardiovascular Disease Diabetes Kidney Disease 59

European Journal of Heart Failure

OCTOBER 3, 2023

Characteristics of heart failure with improved ejection fraction (HFimpEF) patients and outcome comparison with heart failure with persistently reduced ejection fraction (pHFrEF). CV mortality is the composite endpoint for CV mortality + urgent transplant + left ventricular assist device implantation. Events per 1000 person-years. #

Heart Failure 40

Heart Failure Exercise Laboratory Transplant 40

Society of Thoracic Surgeons - Critical Care

MARCH 2, 2022

The researchers reported that 28 patients (93.3%) survived VV-ECMO. months since the patients were treated with VV-ECMO, survival was 86.7%, including one patient who underwent lung transplantation. A 6-minute walk test was performed in 16 patients (59.3%) with a median value of 350 meters, which the researchers called “encouraging.”

COVID-19 40

COVID-19 Cardiothoracic ICU Allied Health 40

Society of Thoracic Surgeons - Research

APRIL 20, 2023

Published Research kschukar Thu, 04/20/2023 - 11:12 Recently published (2016 – present) manuscripts utilizing STS data: Adult Cardiac Surgery, General Thoracic Surgery, Congenital Heart Surgery, and Intermacs/Pedimacs.

Research 52

Research Coronary Artery Bypass Graft Aortic valve Congenital 52

Cardiology Update

APRIL 9, 2024

The percent change from baseline in fasting triglycerides (TG) at six months served as the primary outcome measure. The percent change from baseline in fasting TG at six months served as the primary outcome measure. Among patients with HFpEF, those who received the shunt experienced poor outcomes than those who did not.

Angina 52

Angina Myocardial Infarction Aortic valve Coronary Artery Disease 52

Society of Thoracic Surgeons - Research

APRIL 20, 2023

Published Research kschukar Thu, 04/20/2023 - 11:12 Recently published (2016 – present) manuscripts utilizing STS data: Adult Cardiac Surgery, General Thoracic Surgery, Congenital Heart Surgery, and Intermacs/Pedimacs.

Research 52

Research Coronary Artery Bypass Graft Aortic valve Congenital 52

Circulation: Heart Failure

FEBRUARY 20, 2024

Background:Black heart transplant patients are at higher risk of acute rejection (AR) and death than White patients. After transplant, Black patients had higher levels of dd-cfDNA, 0.09% (interquartile range, 0.001–0.30) compared with White patients, 0.05% (interquartile range, 0.001–0.23;P=0.003).

Heart Transplant 40

Heart Transplant Transplant Heart Failure Outcomes 40

European Journal of Heart Failure

NOVEMBER 7, 2023

BNP, CMR-LVEF and SUVmax in FDG-PET: independent predictors of outcome in a contemporary cardiac sarcoidosis population remaining robust in subgroup subanalysis. Here, we describe baseline characteristics at presentation along with prognosis and predictors of outcome in a sizable and deeply phenotyped contemporary cohort of CS patients.

Sudden Cardiac Death 40

Sudden Cardiac Death Outcomes Heart Transplant Heart Failure 40

European Journal of Heart Failure

DECEMBER 1, 2024

Summary of key study outcomes. Methods and results This single-centre retrospective study examined midterm (180 days) outcomes of patients with CS supported by Impella 5+ who achieved heart recovery. The objective of the study is to examine whether Impella 5.0/5.5 The average duration of Impella support was 10.5 ± 8 days.

Cardiogenic Shock 40

Cardiogenic Shock Heart Transplant Outcomes Transplant 40

Dr. Malcolm Kendrick

OCTOBER 30, 2024

As outlined by the Telegraph newspaper in the UK: ‘The British Sugar Bureau put out a press release dismissing Yudkin’s claims as “emotional assertions” and the World Sugar Research Organisation described his book as “science fiction”. He discovered this by using the conspiratorial activity called…research.

Cholesterol 145

Cholesterol Article Research Diet 145